
In our November SCGE Spotlight, we're covering: - Two consortium publications - Updates to the Gene Therapy Trial Browser - Recording from our SCGE Workshop linkedin.com/pulse/scge-spot…

The Somatic Cell Genome Editing Consortium is funded by the @NIH_CommonFund. Retweets ≠ endorsements. Visit the SCGE Platform scge.mcw.edu/platform/

In our November SCGE Spotlight, we're covering: - Two consortium publications - Updates to the Gene Therapy Trial Browser - Recording from our SCGE Workshop linkedin.com/pulse/scge-spot…

Here, researchers performed in vivo cytometry using magnetic particle imaging (MPI) to track magnetically labeled cells on a timescale of minutes with high sensitivity, zero background signal, and simple linear quantification. science.org/doi/10.1126/scia…

PDUFA plays a critical role in supporting FDA review of innovative therapies, including cell and gene therapies. Join us for our next free Regulatory Webinar on December 9, where regulatory experts will provide an overview of the PDUFA negotiation process, key themes emerging from public input, expectations for congressional reauthorization, and important considerations for stakeholders across the CGT field. Learn more and register now: bit.ly/4zPqQQk

It's time! We are now accepting abstract submissions for #ASGCT2027! Put your discoveries in front of the largest gathering of the cell and gene therapy community, happening May 3-7, 2027, in Philadelphia. Submit by January 15, 2027, at 11:59 PM ET. Learn more about submission categories, guidelines, and more at annualmeeting.asgct.org/abst…

Here, researchers' findings establish AAV-vectorized cytokines as a durable, locally delivered immuno-gene therapy platform for high-grade gliomas. cell.com/molecular-therapy-f…

Here, researchers are developing a 14.3 kDa anti-CD8 VHH tracer (B), along with a nonbinding control tracer (C), in order to track CD8+ (“cytotoxic”) T cells in malignant tumors during immunotherapy by Positron Emission Tomography (PET). pmc.ncbi.nlm.nih.gov/article…

ICYMI - New FDA Guidance Document: Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management fda.gov/regulatory-informati…

The 2026 Breakthroughs abstracts are now live! Get a preview of the latest research and scientific advancements being presented at #ASGCTBreakthroughs, happening Nov. 12-13 in Nashville and virtually. There's still time to register and join experts from across the cell and gene therapy field as they share emerging research, innovative approaches and new developments shaping the future of CGT. Explore the abstracts and register today: asgct.org/breakthroughs

A powerful gene-editing technique has been used to edit DNA directly in a person’s body — the first known instance of such a treatment. go.nature.com/4iC2gMn

In this review, researchers summarize some current strategies to scale-up the production of nanomedicines for translational investigations. sciencedirect.com/science/ar…

Hot off the press! 📢 Our Q3 2026 Gene, Cell and RNA Therapy Landscape Report, developed with Citeline, is here. Explore seven new approvals, an expanding clinical pipeline and the latest advancements shaping the field. Read more: bit.ly/4ufliLp #ASGCT #CGT

We're back with another SCGE Spotlight! This month, we've got: - 2 recent publications - Links to our "Meet the Expert" webinar series recordings - Upcoming SCGE researcher presentations at ASGCT Breakthroughs linkedin.com/pulse/scge-spot…

On September 29th, the SCGE hosted a public workshop titled “Rethinking Clinical Delivery, Regulation, and Payment Models for Individualized Platform-Based Genome Editing Therapies”. The recording for this workshop is available now at: youtube.com/watch?v=5FnuGKb1…

New piece in @CGT_Insights on scaling individualized CRISPR therapeutics: The technical challenge: conventional biomanufacturing optimizes for volume, but individualized gene therapy requires treating each patient as their own 'batch.' @somaticediting 10.18609/cgti.2026.087

Here, SCGE researchers demonstrate that selective organ targeting (SORT) lipid nanoparticles (LNPs) encapsulating optimized Cas9 cargo facilitate efficient, local delivery to skeletal muscle. cell.com/molecular-therapy-f…

Here, a team including SCGE researchers have developed a cost-effective mass-production method for manufacturing vascularized kidney organoids, which has improved production efficiency by more than 50 times compared to conventional culture systems. pmc.ncbi.nlm.nih.gov/article…